ÀÓ¼±¹Î
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : Æó¾Ï, À¯¹æ¾Ï, °©»ó¼±¾Ï, ÇǺξÏ, Èñ±Í¾Ï
Á÷
ˤ
: Á¶±³¼ö
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
31
ÇØ¿Ü
A multicenter phase II study of sorafenib in combination with erlotinibin patients with advanced non-small cell lung cancer (KCSG-0806)
30
ÇØ¿Ü
Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
29
ÇØ¿Ü
Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma
28
ÇØ¿Ü
Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma
27
ÇØ¿Ü
Safety and efficacy of single-agent docetaxel administered weekly in non-small-cell lung carcinoma patients in Korea: an observational study
26
ÇØ¿Ü
Lack of ROS1 gene rearrangement in glioblastoma multiforme
25
ÇØ¿Ü
Quantitative Analysis of ERK Signaling Inhibition in Colon Cancer Cell Lines Using Phospho-Specific Flow Cytometry
24
ÇØ¿Ü
Treatment Outcome of Patients with Anaplastic Thyroid Cancer: A Single Center Experience
23
ÇØ¿Ü
Comparison of Two Inflammation-Based Prognostic Scores in Patients with Unresectable Advanced Gastric Cancer
22
ÇØ¿Ü
Association between Obesity Indices and Insulin Resistance among Healthy Korean Adolescents: The JS High School Study.
1
2
3
4
5
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729